drugset / Trial / NCT02114346

High Dose Atorvastatin for Preventing Contrast-induced Nephropathy

NCT02114346

Phase 2/3 Completed 250 enrolled Isfahan University of Medical Sciences
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of this study is to determine the efficacy of atorvastatin in the prevention of contrast-induced nephropathy in patients undergoing computed tomography coronary angiography. Investigators assume that atorvastatin is effective in this regard. Investigators include patients referring for elective computed tomography coronary angiography and allocate them to atorvastatin or placebo from 24 hours before to 48 hours after administration of contrast material. Investigators then measure serum creatinine and see if it is raised by ≥ 0.5 mg/dL or ≥ 25% of the baseline value.

Timeline

Start
2013-07
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg Oral
Background sodium chloride Unknown

Indications

No indication recorded.